• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Toolbar - View Selection
 
Items 1 of 1
ALX-380-090 Revised 12-Mar-08
Tryprostatin A
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics for Cytoskeletal Research
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-090-C500   500 µg 179.00 USD Add To Cart
Product Specification
FORMULA: C22H27N3O3
MW: 381.5
SOURCE/HOST: Isolated from Aspergillus fumigatus.
PURITY: ≥90%
APPEARANCE: White powder.
SOLUBILITY: Soluble in methanol, 100% ethanol or DMSO.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description
Diketopiperazine. Arrests cell cycle progression at the G2/M phase. Inhibitor of MAP-dependent microtubule assembly. Inhibits the ABC-transporter breast cancer resistance protein (BCRP) and thereby reverses the resistance of cancer cells against antitumor drugs.
Product Specific Literature References
Tryprostatins A and B, novel mammalian cell cycle inhibitors produced by Aspergillus fumigatus: C.B. Cui, et al.; J. Antibiot. 48, 1382 (1995) Abstract
Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. I. Taxonomy, fermentation, isolation and biological properties: C.B. Cui, et al.; J. Antibiot. 49, 527 (1996) Abstract
Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. II. Physico-chemical properties and structures: C.B. Cui, et al.; J. Antibiot. 49, 534 (1996) Abstract
Tryprostatin A, a specific and novel inhibitor of microtubule assembly: T. Usui, et al.; Biochem. J. 333, 543 (1998) Abstract; Full Text
Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A: H. Woehlecke, et al.; Int. J. Cancer 107, 721 (2003) Abstract
 
 

Your items will be kept only for the duration of your visit.